We show that CCT3833 does not drive paradoxical activation of the RAF/MEK/ERK pathway in KRAS-mutant cells and that its ability to exert dual inhibition of RAF and SRC provides effective therapy in preclinical KRAS-mutant PDAC, CRC and NSCLC models. The gene discussed is SRC; the disease is non-small cell lung carcinoma.